Health

ImmuneAdvice GmbH is a pre-seed, preclinical radiopharmaceutical start-up based in Reutlingen, Germany, developing next-generation immune cell tracers (ICE-Ts) for PET imaging. Our lead candidate, CD4 ICE-T, non-invasively identifies the immune status of tumors – distinguishing “hot” from “cold” microenvironments – and enables early detection of resistance to immune checkpoint inhibitors (ICIs). By providing actionable insights into a patient’s response to immunotherapy, our ICE-Ts open the door to timely, personalized treatment adjustments, especially for melanoma and NSCLC patients – redefining cancer care.

Ovo Labs is developing therapeutics to improve egg quality and increase IVF success rates, particularly for women in their mid-30s to early 40s. Currently, no treatments exist to enhance egg quality, which declines significantly with age—resulting in only a 13% chance of conception by age 40. Ovo Labs builds on 20 years of pioneering research in the field of female infertility in the laboratory of Prof. Melina Schuh and holds an exclusive global license covering an entire portfolio of therapeutic candidates targeting egg quality. The company raised its Seed Round in 2025 in order to take its Lead Therapeutic, EmbryoProtect1, towards clinical studies in humans

NeutroGen Therapeutics (NTX) is developing a novel allogeneic neutrophil cell therapy for neutropenia—a condition prevalent in leukemia patients and individuals undergoing chemotherapy, associated with high infection risk and mortality. NTX’s patent-pending therapy uses a stem cell-based protocol that enables the production of storable, genetically modifiable neutrophils, providing a faster, more reliable treatment. The platform also holds promise for expansion into cancer, autoimmunity, and multi-drug resistance indications.

Kyron.bio is pioneering a new frontier in drug design by engineering therapeutic production cells to precisely control the sugars that coat protein surfaces. These sugar molecules dramatically influence therapeutic function and performance. Kyron.bio’s technology has demonstrated the ability to prevent unwanted immune responses to antibody therapies and enhances the stability and efficacy of protein-based drugs used in treating cancer, autoimmune diseases, and other conditions, addressing critical unmet clinical needs.

Aitiologic is a precision diagnostics company pioneering the next generation of liquid biopsy. Its patented aitios®platform integrates artificial intelligence with multi-modal DNA profiling to decode previously inaccessible molecular signals from blood – enabling early, non-invasive detection of treatable diseases. Beginning with prenatal care, Aitiologic is developing an AI-powered blood test to detect hundreds of treatable fetal conditions – before symptoms arise and ahead of conventional diagnostics – giving every child the best possible start to a healthy life. With broader applications spanning maternal health and oncology, Aitiologic is redefining how and when we detect disease – transforming early insight into timely intervention and better outcomes at every stage of life.

Captain T Cell is advancing next-generation TCR-T cell therapies to overcome the limitations of immunotherapy in solid tumors. Its proprietary genetic “toolbox” enables T cells to achieve complete responses in preclinical models at a fraction of the dose used by competitors, unlocking automated, scalable manufacturing at significantly lower cost. With a best-in-class autologous program quickly approaching the clinic and a first-in-class allogeneic “off-the-shelf” platform showing complete responses in preclinical models, Captain T Cell is well-positioned to deliver impactful therapies. Backed by a combination of private investment and significant non-dilutive funding, the company offers a potentially game-changing approach in a rapidly growing market.

SoundCell developed the MelodyOne: a rapid nanotechnology Antimicrobial Susceptibility Testing (AST) platform that detects bacterial resistance within just 1 hour, far faster than traditional methods. Using graphene-based sensors, it measures microscopic bacterial vibrations to determine if antibiotics are working in real time. With quicker AST results, physicians can promptly switch from broad-spectrum to narrow-spectrum antibiotics, promoting more prudent antibiotic use and allowing patients to receive effective treatments sooner. The cornerstone of their technology lies in leveraging bacterial nanomotion to assess antibiotic susceptibility. This approach bypasses the need for bacterial growth rates, which is the limiting factor in current systems that require up to two days to provide results.